Baseline differences in HbA1c and triglycerides between groups could have influenced outcomes, although the primary findings were robust
The safety concern is different
It is NOT due to people with obesity not having enough willpower
Apr 8, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 1,814 views The risk of side effects with GLP-1 therapies varies widely among patients, yet treatment decisions often overlook this variability
1 "We're not only lowering the cost of medications, we're also connecting members to real, human care: specialists in obesity and diabetes, clinical pharmacists, and ongoing nutritional support with registered dietitiansall from the comfort of home." READ MORE: Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips
I tried phentermine 37.5 mg from [date] to [date] and lost only 3% of body weight, below the 5% threshold